NasdaqGS:EXELBiotechs
Exelixis [NasdaqGS:EXEL] Sees US$555 Million Revenue With Earnings Up Sharply
Exelixis (NasdaqGS:EXEL) recently announced its impressive first-quarter earnings for 2025, with revenue and net income showing substantial growth. This financial performance, coupled with the FDA approval of CABOMETYX for new indications, likely contributed to the company's 12.65% share price increase over the last quarter. The company's share repurchase program announcement also adds potential upward pressure, reflecting confidence in its future prospects. Given the broader market's 12%...